1023 related articles for article (PubMed ID: 29878845)
1. Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis.
Hohenester S; Christiansen S; Nagel J; Wimmer R; Artmann R; Denk G; Bischoff M; Bischoff G; Rust C
Am J Physiol Gastrointest Liver Physiol; 2018 Sep; 315(3):G329-G338. PubMed ID: 29878845
[TBL] [Abstract][Full Text] [Related]
2. Multidisciplinary lifestyle intervention is associated with improvements in liver damage and in surrogate scores of NAFLD and liver fibrosis in morbidly obese patients.
Bischoff M; Zimny S; Feiner S; Sauter J; Sydor S; Denk G; Nagel JM; Bischoff G; Rust C; Hohenester S
Eur J Nutr; 2022 Aug; 61(5):2725-2735. PubMed ID: 35277756
[TBL] [Abstract][Full Text] [Related]
3. Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease.
López IC; Aroca FG; Bernal MDF; Mompeán JAL; Bernal ÁB; Martínez AMH; Barba EM; Velasco JAN; Paricio PP
Obes Surg; 2017 Sep; 27(9):2347-2353. PubMed ID: 28229316
[TBL] [Abstract][Full Text] [Related]
4. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
Vilar-Gomez E; Martinez-Perez Y; Calzadilla-Bertot L; Torres-Gonzalez A; Gra-Oramas B; Gonzalez-Fabian L; Friedman SL; Diago M; Romero-Gomez M
Gastroenterology; 2015 Aug; 149(2):367-78.e5; quiz e14-5. PubMed ID: 25865049
[TBL] [Abstract][Full Text] [Related]
5. Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients.
Lassailly G; Caiazzo R; Buob D; Pigeyre M; Verkindt H; Labreuche J; Raverdy V; Leteurtre E; Dharancy S; Louvet A; Romon M; Duhamel A; Pattou F; Mathurin P
Gastroenterology; 2015 Aug; 149(2):379-88; quiz e15-6. PubMed ID: 25917783
[TBL] [Abstract][Full Text] [Related]
6. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
[TBL] [Abstract][Full Text] [Related]
7. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
[TBL] [Abstract][Full Text] [Related]
8. CORRELATION BETWEEN NONALCOHOLIC FATTY LIVER DISEASE FEATURES AND LEVELS OF ADIPOKINES AND INFLAMMATORY CYTOKINES AMONG MORBIDLY OBESE INDIVIDUALS.
Baltieri L; Chaim EA; Chaim FDM; Utrini MP; Gestic MA; Cazzo E
Arq Gastroenterol; 2018; 55(3):247-251. PubMed ID: 30540086
[TBL] [Abstract][Full Text] [Related]
9. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.
Bechmann LP; Kocabayoglu P; Sowa JP; Sydor S; Best J; Schlattjan M; Beilfuss A; Schmitt J; Hannivoort RA; Kilicarslan A; Rust C; Berr F; Tschopp O; Gerken G; Friedman SL; Geier A; Canbay A
Hepatology; 2013 Apr; 57(4):1394-406. PubMed ID: 23299969
[TBL] [Abstract][Full Text] [Related]
10. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
[TBL] [Abstract][Full Text] [Related]
11. What Is the Role of the New Index Relative Fat Mass (RFM) in the Assessment of Nonalcoholic Fatty Liver Disease (NAFLD)?
Machado MV; Policarpo S; Coutinho J; Carvalhana S; Leitão J; Carvalho A; Silva AP; Velasco F; Medeiros I; Alves AC; Bourbon M; Cortez-Pinto H
Obes Surg; 2020 Feb; 30(2):560-568. PubMed ID: 31637670
[TBL] [Abstract][Full Text] [Related]
12. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
[TBL] [Abstract][Full Text] [Related]
13. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
14. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive lifestyle intervention
Deibert P; Lazaro A; Schaffner D; Berg A; Koenig D; Kreisel W; Baumstark MW; Steinmann D; Buechert M; Lange T
World J Gastroenterol; 2019 Mar; 25(9):1116-1131. PubMed ID: 30862999
[TBL] [Abstract][Full Text] [Related]
16. Histologic spectrum of nonalcoholic fatty liver disease in morbidly obese adolescents.
Xanthakos S; Miles L; Bucuvalas J; Daniels S; Garcia V; Inge T
Clin Gastroenterol Hepatol; 2006 Feb; 4(2):226-32. PubMed ID: 16469684
[TBL] [Abstract][Full Text] [Related]
17. Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease.
Ma H; Gomez V; Lu L; Yang X; Wu X; Xiao SY
J Gastroenterol Hepatol; 2009 Feb; 24(2):233-7. PubMed ID: 18713296
[TBL] [Abstract][Full Text] [Related]
18. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research.
Gottlieb A; Mosthael W; Sowa JP; Canbay A
Digestion; 2019; 100(2):79-85. PubMed ID: 30537758
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease.
Wong VW; Wong GL; Chan RS; Shu SS; Cheung BH; Li LS; Chim AM; Chan CK; Leung JK; Chu WC; Woo J; Chan HL
J Hepatol; 2018 Dec; 69(6):1349-1356. PubMed ID: 30142427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
